IQVIA

IQVIA to Announce Fourth-Quarter and Full-Year 2023 Results on February 14, 2024

Retrieved on: 
Wednesday, January 24, 2024
Health Technology, Data Management, Other Health, Technology, Pharmaceutical, Managed Care, Clinical Trials, Other Technology, Science, Biotechnology, Software, Networks, Other Science, Health, Research, IQVIA, ID, IQV, Webcast

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its fourth-quarter and full-year 2023 financial results before the market opens on Wednesday, February 14, 2024.

Key Points: 
  • IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its fourth-quarter and full-year 2023 financial results before the market opens on Wednesday, February 14, 2024.
  • The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day.
  • The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com .
  • To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com .

Virginia Doetsch Named Manager of the Year for Julia B. Fee Sotheby's International Realty

Retrieved on: 
Tuesday, January 16, 2024
Sotheby, Doetsch, IQVIA, Sotheby's International Realty, Mentorship, Real estate

BRONXVILLE, N.Y., Jan. 16, 2024 /PRNewswire-PRWeb/ -- Julia B. Fee Sotheby's International Realty today announced that Virginia Doetsch, manager of the firm's Irvington and Bronxville, N.Y., brokerages, has been named the company's 2023 Manager of the Year. Doetsch, who has served as a brokerage manager with Julia B. Fee Sotheby's International Realty for 13 years, was chosen from among 18 managers for the honor. This is the seventh time Doetsch has been recognized with this award.

Key Points: 
  • Fee Sotheby's International Realty today announced that Virginia Doetsch, manager of the firm's Irvington and Bronxville, N.Y., brokerages, has been named the company's 2023 Manager of the Year.
  • Doetsch, who has served as a brokerage manager with Julia B.
  • Fee Sotheby's International Realty for 13 years, was chosen from among 18 managers for the honor.
  • "I am proud to announce Virginia Doetsch as our Manager of the Year, an honor well deserved," said Paul Breunich, Chairman and Chief Executive Officer of Julia B.

Pharmaceutical Contract Research and Manufacturing (CRAM) Market size to grow by USD 121.35 billion from 2022 to 2027; Asia to account for 41% of market growth - Technavio

Retrieved on: 
Tuesday, January 16, 2024
ChromeOS, Catalent, Recipharm, Parexel, ROW, Geography, Biotechnology, Syneos Health, Thermo Fisher Scientific, ICON PLC, ICON, CMO, CRAM, USD, Free, Lupin Limited, Research, IQVIA, Growth, Fine chemical

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The pharmaceutical contract research and manufacturing (CRAM) market is expected to grow by USD 121.35 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The pharmaceutical contract research and manufacturing (CRAM) market is expected to grow by USD 121.35 billion from 2022 to 2027.
  • In addition, the momentum of the market will progress at a CAGR of 10.32% during the forecast period, according to Technavio Research.
  • For additional data on Market Size (2017) Historic Year, Market Size - Forecasted Year, Historic Opportunity (2017-2021), Historic CAGR, Forecasted Opportunity (2023-2027), Market Opportunity Transformation Growth, and Market Opportunity Capitalization.
  • Pharmaceutical Contract Research And Manufacturing (CRAM) Market: Segmentation Analysis
    The market share growth of the CMO segment will be significant during the forecast period.

Mucinex and TV Personality Nick Viall Celebrates New Product with Pop-Up Café Offering New Yorkers Free Coffee

Retrieved on: 
Monday, January 15, 2024
IQVIA, Congestion, Sore throat, New Yorker, Life, Kick start, Reckitt, Viall, Work, Coffee, Fever, Transport, Sensation, Marketing, Dietary supplement

PARSIPPANY, N.J., Jan. 15, 2024 /PRNewswire/ -- When you're suffering from cold and flu symptoms – whether it be a cough, congestion, sore throat, or fever – symptoms seem to feel worse when we first wake up. And if you're a busy person on the go, this can be especially disruptive to an already long day ahead.

Key Points: 
  • And if you're a busy person on the go, this can be especially disruptive to an already long day ahead.
  • "And when those disruptive cold and flu symptoms do hit, we always feel worse upon waking up.
  • Mucinex Kickstart provides powerful fast-acting multi-symptom relief and instant cooling sensation, giving consumers that morning kick to help them make a strong come back."
  • As part of this experience, New Yorkers will be treated to a complimentary cup of coffee, served by a fleet of baristas and award-winning podcast host, TV personality, and bestselling author Nick Viall the morning January 17th.

$22.4 Bn Pharmacovigilance Global Market Opportunities and Strategies to 2032 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 10, 2024
Health, Pharmaceutical, Conditional sentence, ADR, IQVIA, Research, Incidence, Hospital, Pharmacovigilance, Developed country, Mining, Accenture, Drug development, ICON PLC, Parexel, Prevalence, Disulfiram-like drug, Clinical trial, Cognizant, Wipro, Ageing, EHR, Growth

The "Pharmacovigilance Global Market Opportunities and Strategies to 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pharmacovigilance Global Market Opportunities and Strategies to 2032" report has been added to ResearchAndMarkets.com's offering.
  • The spontaneous reporting market was the largest segment of the pharmacovigilance market by type, accounting for $2.2 billion or 32.8% of the total market in 2022.
  • North America was the largest region in the pharmacovigilance market, accounting for 44.0% of the global market in 2022.
  • The global pharmacovigilance market is fragmented, with a large number of players operating in the market.

FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara® (Ustekinumab)

Retrieved on: 
Friday, January 5, 2024
Health, FDA, Other Health, Research, Science, Pharmaceutical, Biotechnology, Food, Ustekinumab, EMA, MAA, Intas Pharmaceuticals, Inflammation, USD, IQVIA, Ulcerative colitis, CSO, Patient, Safety, Psoriasis, Psoriatic arthritis, BLA, Pharmaceutical industry

The BLA leverages the analytical similarity assessment data between EU and US sourced Stelara® and DMB-3115.

Key Points: 
  • The BLA leverages the analytical similarity assessment data between EU and US sourced Stelara® and DMB-3115.
  • It recorded USD 17.77 billion in sales (IQVIA Accumulative Sales) in 2022 and is one of the world’s best-selling biologics.
  • The rights of Dong-A Socio Holdings for R&D and commercialization were transferred to Dong-A ST in July 2020 for efficient project management.
  • Intas Pharmaceuticals plans to commercialize DMB-3115 through Accord BioPharma (US), Accord Healthcare (EU, UK, and Canada), and other subsidiaries around the world.

Flash News: OKX Wallet and OneKey Collaborate to Reward Users with Limited-Edition NFTs

Retrieved on: 
Wednesday, December 27, 2023
IQVIA, OKX, Non-fungible token, NFT, Web3, Cryptocurrency

OKX Wallet and OneKey , a renowned provider of crypto hardware wallets, today announced their collaboration to offer users the chance to claim a limited-edition NFT, titled: ' OKX x Onekey Limited NFT. '

Key Points: 
  • OKX Wallet and OneKey , a renowned provider of crypto hardware wallets, today announced their collaboration to offer users the chance to claim a limited-edition NFT, titled: ' OKX x Onekey Limited NFT. '
  • For the opportunity to claim the limited-edition NFT, users must complete various social media-related tasks, such as following OKX Web3 and OneKey on X (formerly known as Twitter) before January 15, 2024.
  • A total of 300 NFTs are available for users who complete these tasks.
  • In addition, 200 extra NFTs will be airdropped to the wallet addresses (selected randomly) of users who have purchased the OKX-OneKey co-branded wallet.

New York Regional Median Home Price Holds Steady Between October and November 2023

Retrieved on: 
Thursday, December 21, 2023
IQVIA, County, Housing, Hudson Valley, Condo, MLS, Haggerty, Sale, Statistics, Real estate

FARMINGDALE, N.Y., Dec. 21, 2023 /PRNewswire/ -- OneKey® MLS is the one source real estate marketplace for monthly statistics for residential real estate transactions from Montauk to Manhattan, north through the Hudson Valley and the Catskill Mountains. For November 2023, OneKey MLS reported a regional closed median sale price of $615,000, a 0.00% change as compared to the figure reported in October 2023. In a year-over-year comparison, the closed median sale price increased 7.00% from $575,000, reported in November 2022. Between October 2023 and November 2023, closed regional sales transactions, including residential, condo, and co-op sales, decreased 11.00% to 3,847 from 4,321. Year-over-year, transactions were down 17.7% from November 2022.  Across the region, pending sales transactions decreased 10.70% in a month-over-month comparison, reportedly 3,828 in November 2023 as compared to 4,288 in October 2023. Year-over-year, pending residential sales were up 1.70% in November, from 3,763 the year prior.

Key Points: 
  • For November 2023, OneKey MLS reported a regional closed median sale price of $615,000, a 0.00% change as compared to the figure reported in October 2023.
  • In a year-over-year comparison, the closed median sale price increased 7.00% from $575,000, reported in November 2022.
  • Between October 2023 and November 2023, closed regional sales transactions, including residential, condo, and co-op sales, decreased 11.00% to 3,847 from 4,321.
  • Five of nine counties reported an increased closed median sale price in a month-over-month comparison, while two counties reported a decreased median sale price, and two reported no change.

CHC brief questions FTC ad market definition in IQVIA merger challenge

Retrieved on: 
Wednesday, December 20, 2023
Federal Trade Commission, Sidley Austin, Sale, 4A, LLP, Acquisition, Complaint, Coalition, IQVIA, FTC, CHC, Lasso, DSPS

In July, the FTC issued an administrative complaint in federal court to block IQVIA from acquiring Propel Media alleging that the proposed acquisition would give the company a market-leading position in programmatic advertising for health care products, namely prescription drugs to health care professionals.

Key Points: 
  • In July, the FTC issued an administrative complaint in federal court to block IQVIA from acquiring Propel Media alleging that the proposed acquisition would give the company a market-leading position in programmatic advertising for health care products, namely prescription drugs to health care professionals.
  • From the FTC's complaint, which is significantly redacted to the public, CHC questioned the agency's narrow and antiquated view that Demand Side Platforms (DSPs) alone "provide programmatic advertising" to advertisers.
  • The CHC urged the court to reject the overly narrow view of "programmatic advertising" advanced by the FTC.
  • The brief was developed in collaboration with CHC and 4A's, and filed by Sidley Austin, LLP with attorneys from its New York and Washington, DC offices.

Harvard Apparatus Regenerative Technology Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Longevity, OTCQB, European Medicines Agency, University, Investment, University of Michigan, Clinical trial, EMA, IQVIA, Patient, Regenerative medicine, European, Clinical professor, E-commerce, Greater, LTD, Mayo Clinic, Pharmaceutical industry, Cryptocurrency, Hong Kong

Holliston, MA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today announced its financial results for the three and nine months ended September 30, 2023.

Key Points: 
  • Holliston, MA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today announced its financial results for the three and nine months ended September 30, 2023.
  • We activated the second clinical trial site with the University of Michigan in August 2023 to expand the screening of patients.
  • In the third quarter of 2023, the Company’s subsidiary in Hong Kong, Harvard Apparatus Regenerative Technology Limited, or HRGN LTD, launched its longevity product business in Asia, generating $40,000 in sales.
  • At September 30, 2023, the Company had operating cash and short-term investments on-hand as of $1.5 million.